Human CD26/DPP4 (YS110) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Dipeptidyl peptidase 4 (CD26/DPP4) is a ~88 kDa protein. Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM.
Product Name:
Human CD26/DPP4 (YS110) Antibody
SKU:
GXBS01043
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
YS110
Target:
TP103
Isotype:
IgG
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
YS110
Biological Activity:
YS110 (0-250 ug/mL, 48 h) inhibits cell proliferation in a concentration dependent manner in NCI-H2452 cells [1]. YS110 (2 ug/mL, 24 h) leads to a significant increase in the proportion of G2/M phase and affects the expression of related proteins in NCI-H2452 cells [1]. YS110 (2 ug/mL, 6-24 h) elevates activating phosphorylation of p38 MAPK and ERK1/2 in NCI-H2452 cells [1]. YS110 (0-20 ug/mL, 48 h) inhibits cell growth of JMN cells in a dose-dependent manner [2]. YS110 (0-4 h) relies on the caveolin pathway to induce CD26 nuclear translocation in JMN cells [2]. YS110 (2 ug/mL, 3 h) significantly inhibits the mRNA and protein levels of POLR2A in JMN cells [2]. YS110 (10 ug/mL, 30 min) effectively inhibits MERS CoV S1-Fc specific binding to CD26 in JKT-hCD26WT cells [3]. YS110 (40 ug/mL, 30 min) significantly reduces MERS CoV infection rate in Huh-7 cells [3]. Cell Proliferation Assay [1] Cell Line: NCI-H2452 cells Concentration: 0, 0.1, 2, 10 and 250 ug/mL Incubation Time: 48 h Result: Inhibited the cell proliferation of NCI-H2452 cells. Cell Cycle Analysis [1] Cell Line: NCI-H2452 cells Concentration: 2 ug/mL Incubation Time: 24 h Result: Significantly increased the proportion of G2/M phase cells with an average increase of 8 %. Western Blot Analysis [1] Cell Line: NCI-H2452 cells Concentration: 2 ug/mL Incubation Time: 6 and 24 h Result: Significantly increased the level of p21, p-cdc2, p-cdc25C, p-p38 MAPK and p-ERK1/2. RT-PCR [2] Cell Line: JMN cells Concentration: 2 ug/mL Incubation Time: 3 h Result: Significantly reduced the mRNA level of POLR2A. Western Blot Analysis [2] Cell Line: JMN cells Concentration: 2 ug/mL Incubation Time: 3 h Result: Significantly reduced the protein level of POLR2A. YS110 (5 mg/kg or 5 ug, intratumoral injection or i.p., three times per week) can significantly inhibit tumor growth in NOG mice bearing JMN xenograft [1]. YS110 (8 mg/kg or 10 ug, intratumoral injection or i.p.
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
